|Title||Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.|
|Publication Type||Journal Article|
|Year of Publication||2021|
|Authors||Conteduca V, Ku S-Y, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M, Wang Y, Dittamore R, Wenstrup R, Mosquera JMiguel, Schonhoft JD, Beltran H|
|Journal||NPJ Precis Oncol|
|Date Published||2021 Aug 12|
Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.
|Alternate Journal||NPJ Precis Oncol|
|PubMed Central ID||PMC8361159|
|Grant List||W81XWH-17-1-0653 / / U.S. Department of Defense (United States Department of Defense) / |
R27CA241486 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
P50 CA211024 / CA / NCI NIH HHS / United States
P50-CA211024 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
R37 CA241486 / CA / NCI NIH HHS / United States
Related Faculty:Juan Miguel Mosquera, M.D.